Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients

Purpose To evaluate the pharmacokinetics of simvastatin at the maximum tolerated dose (MTD) of 7.5 mg/kg, twice daily, in the context of a pilot trial enrolling patients with recurrent and refractory chronic lymphocytic leukemia.